Loading…
Loading…
BOSTON, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced it has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED (“ARCHIMED”), a leading investment firm focused exclusively on healthcare industries.
Standard BioTools Enters into New Purchase Agreement with Element Biosystems, a Subsidiary of GMT Venture, After Determining GMT Venture's Unsolicited Acquisition Proposal as Superior Standard BioTools Enters into New Purchase Agreement with Element Biosystems, a Subsidiary of GMT Venture, After Determining GMT Venture's Unsolicited Acquisition Proposal as Superior
Are SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Sept. 11, 2026Insiders may stand to receive substantial financial bene
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Proxy and Looming Shareholder Merger Vote --VRME, VAL, LAB and FTHM
INVESTOR ALERT: The M&A Class Action Firm Launches Investigation of the Merger--IRDM, VRME, VAL and LAB PR Newswire
BOSTON, Mass. , Aug. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the "Company" or "Standard BioTools") today announced financial results for the quarter ended June 30, 2026. Recent Highlights: Second quarter 2026 revenue of $20.
BOSTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended June 30, 2026.